Chartered Accountant for Pharmacies & Officines: The Complete 2026 Guide

A French pharmacy (officine) is a uniquely complex business, combining the constraints of a regulated health profession with those of a commercial enterprise subject to market pressures. In 2026, pharmacy owners face multi-rate VAT, evolving ROSP (public health incentive) targets, structural reforms to the economic model, and increasing pressure on margins.

This guide covers the key areas where a specialist chartered accountant (expert-comptable) adds value for pharmacy owners in France.

For full detail, please refer to the French version of this guide above.

Key areas covered#

• Multi-rate VAT management (2.1%, 5.5%, 10%, 20%) and LGO software integration
• Legal structures: SEL (SELARL/SELAS), SPFPL (pharmacy holding company)
• Owner remuneration optimisation: salary vs dividends arbitrage
• CAVP retirement planning and supplementary savings (PER, Madelin contracts)
• ROSP: calculation, provisioning and optimisation
• Stock management and working capital (BFR)
• Pharmacy valuation and transfer (LBO, OBO, Dutreil)
• Payroll under the pharmacy collective agreement (IDCC 1996)
• Digital tools: LGO integration, monthly dashboards, e-invoicing compliance

A French pharmacy (officine) is a business unlike any other. It combines the constraints of a regulated health profession, with its professional duties, its agreements with the public health insurer (Assurance Maladie) and its public service obligations, alongside those of a retail business exposed to market forces, margin pressure and the growing competition of buying groups. In 2026, this dual nature has sharpened further: pharmacists must absorb new missions (vaccinations, pharmaceutical interviews, teleconsultation, rapid screening tests), manage multi-rate VAT of considerable complexity, and anticipate the effects of a structural reform of the pharmacy economic model that has been underway for several years.

In this context, the chartered accountant (expert-comptable) is no longer a simple provider who produces your annual accounts once a year. They become a genuine co-pilot of your pharmacy: analysing your margin in real time, structuring your legal arrangements, optimising your remuneration, steering your social protection, preparing you for transfer and supporting every strategic decision. This guide answers the questions a pharmacy owner, employed pharmacist or prospective buyer asks about the role of a specialist pharmacy accountant.

The turnover of a pharmacy is built around five main categories, each with its own margin and VAT regime. Reimbursable medicines (with a regulated retail margin) typically represent 55 to 65 percent of turnover and are taxed at 2.1 percent. Non-reimbursable medicines (over-the-counter advice products) account for 10 to 15 percent at the 10 percent VAT rate with a free margin. Parapharmacy and cosmetics make up 8 to 12 percent at 20 percent. Medical equipment such as orthopaedics and home care devices represents 3 to 7 percent at 5.5 percent. Finally, dispensing fees account for 5 to 12 percent, taxed at 2.1 percent.

The dispensing fee, introduced progressively since 2017, now represents a growing share of pharmacy results. It is paid by the Assurance Maladie directly to the pharmacy and rewards the act of dispensing independently of the price of the medicine. In 2026, it is a major lever for improving the profit and loss account.

Gross margin is the key indicator of a pharmacy. It averages between 28 and 34 percent of turnover including VAT, and varies sharply according to the generic substitution policy, the product mix (the ratio of reimbursable medicines to OTC and parapharmacy), negotiations with laboratories and wholesalers (year-end rebates), and location (urban, rural or shopping-centre pharmacy). A two-point difference in gross margin on a pharmacy with 2 million euros of turnover represents 40,000 euros of additional profit. That is precisely the lever a specialist accountant helps you identify and pull.

On the cost side, purchases of goods net of rebates weigh 68 to 72 percent of turnover, staff costs excluding the owner 12 to 16 percent, rent and rental charges 2 to 4 percent, depreciation 0.5 to 1.5 percent, financial charges 1 to 3 percent and other external charges 2 to 4 percent. The pre-tax operating result of a well-run pharmacy oscillates between 8 and 14 percent of turnover including VAT. Below 8 percent, corrective measures are needed; above 14 percent, the pharmacy is being managed excellently.

VAT management is probably the most sector-specific tax complexity an officine faces. Unlike most retailers, who apply a single rate, a pharmacy juggles four distinct rates every day. The 2.1 percent rate applies to reimbursable medicines, reimbursable magistral preparations, generic-register specialities and dispensing fees. The 10 percent rate covers non-reimbursable medicines, including non-reimbursed plant-based medicines and non-reimbursed oral contraceptives. The 5.5 percent rate applies to medical devices for diabetics, home-care equipment on a restrictive list set by decree, and equipment for disabled persons. The 20 percent rate covers parapharmacy, cosmetics, non-medicinal food supplements and common medical equipment not on a list.

Several product categories regularly generate rate errors that can trigger a tax reassessment. Magistral preparations depend on the nature of the substances used and whether they are reimbursable. Homeopathic medicines have been non-reimbursable since 2021 and are therefore taxed at 10 percent rather than 2.1 percent. Connected medical devices qualify for 5.5 percent only under strict conditions. Rapid screening tests are taxed at 20 percent except where a convention provides otherwise. Infant formula on prescription is taxed at 5.5 percent if it is a medicine and 20 percent if it is a food supplement. A specialist pharmacy accountant configures your dispensing software (LGO, such as Winpharma, Lgpi, Opus or Pluspharmacie) to automate the split by VAT rate and make your monthly CA3 returns reliable.

A pharmacy is generally subject to standard-regime VAT, with a monthly CA3 return. The VAT collected at each rate is determined from the daily Z tickets of the dispensing software, the automated feed via the LGO to accounting software connection, and a monthly consistency check that reconciles sales turnover, returns and till discrepancies. Input VAT on purchases is fully recoverable: a pharmacy is not subject to a deduction proportion unless it carries on an exempt activity such as renting out space.

A pharmacy owner may practise in their own name, falling under the non-commercial profits (BNC) regime. This is historically the most common but has major drawbacks: personal income tax on the entire profit even when not drawn, social contributions on the net BNC profit (around 45 to 48 percent of self-employed contributions), no separation between the pharmacy and personal assets, and little room to optimise through dividends. A pharmacist with a BNC profit of 150,000 euros will pay roughly 70,000 to 75,000 euros in CAVP and URSSAF contributions plus income tax (at a 41 percent marginal rate), a combined tax and social burden of nearly 50 percent.

The Société d'Exercice Libéral (SELARL with limited liability or SELAS as a simplified joint-stock company) allows a move to corporation tax (IS) and is the recommended structure from 80,000 to 100,000 euros of net profit. Social contributions are then based only on the remuneration actually paid; undistributed profit is taxed at IS (15 percent up to 42,500 euros, 25 percent above); dividends bear roughly 17.2 percent of social levies; remuneration can be fully arbitraged between salary and dividends; and personal assets are separated. For a pharmacy profit of 200,000 euros, BNC practice leaves net income of around 105,000 euros after roughly 95,000 euros of social charges and income tax. In a SELARL at IS with a salary of 80,000 euros, social charges fall to around 40,000 euros and IS on the 120,000 euros of residual profit is 15,000 euros at the reduced rate plus 5,000 euros at the standard rate, leaving net income (net salary plus retained cash) of around 140,000 euros. The gain can exceed 35,000 euros a year, more than 350,000 euros over a ten-year career.

The Société de Participations Financières de Profession Libérale (SPFPL) is the holding company specific to pharmacists. It holds the SEL shares and serves several purposes. First, the leveraged buy-out: the SPFPL borrows to acquire the SEL shares, and dividends flowing up from the SEL benefit from the parent-subsidiary regime (95 percent of dividends received are exempt, only a 5 percent share of costs and charges is taxable, an effective tax of 1.25 percent on the dividends), which repays the acquisition loan without passing through the pharmacist's personal income. Second, multi-pharmacy ownership: the reform of 5 April 2005, completed by the HPST law, allows a pharmacy owner to hold up to five pharmacies through an SPFPL, with the holding centralising inter-pharmacy financial flows. Third, the owner buy-out: the pharmacist sells SEL shares to their own SPFPL, recovering capital that is untaxed or lightly taxed on the capital gain, monetising part of the pharmacy's value without selling it. Fourth, bringing in a junior partner: the SPFPL allows an employed pharmacist to become a partner by acquiring holding shares without altering the operating SEL. The SPFPL is subject to specific ownership rules (only practising pharmacists may be majority partners) and to approval from the professional body; the accountant works with a specialist lawyer to secure these arrangements.

In a SELARL at IS, the pharmacy owner has four ways to draw income that must be finely arbitraged. Manager or president remuneration is deductible from the company's taxable result and bears self-employed contributions (majority SELARL manager) or employee-equivalent contributions (SELAS president). Dividends are distributed after IS and then taxed at the flat tax (PFU) of 31.4 percent (12.8 percent income tax plus 18.6 percent social levies), or on election at the progressive scale; in a SELARL with a majority manager, dividends above 10 percent of capital plus current account bear self-employed contributions on top of the social levies, a frequent trap. A remunerated partner current account lets the pharmacist advance funds and receive interest that is deductible for the company within the BOFiP rate in force. Finally, in certain partial-transfer arrangements with a young partner, the seller may receive a fee for leasing the goodwill, with a specific tax regime to study.

As a guide, on a SELARL result before remuneration of 100,000 euros, around 60,000 euros gross of salary and 15,000 euros net of dividends gives a net tax and social burden of about 42 percent; at 200,000 euros, 90,000 euros gross and 40,000 euros net brings it to about 38 percent; at 300,000 euros, 100,000 euros gross and 80,000 euros net brings it to about 36 percent. These ranges are indicative and depend on family situation, marital regime, any property income and patrimonial objectives. As a general rule, for owners in a SELARL with turnover above 1.5 million euros, self-employed status via the SELARL usually remains more advantageous on overall cost, provided social protection is supplemented with a Madelin contract (provident and supplementary pension cover).

The Caisse d'Assurance Vieillesse des Pharmaciens (CAVP) is the compulsory pension fund for all pharmacists registered with the professional body. It runs a basic scheme proportional to professional income, a points-based supplementary scheme by bracket, and progressive retirement available from age 60 under conditions. For 2026, the basic plus supplementary contribution is around 8.23 percent on the first PASS, around 1.87 percent between one and four PASS, with the supplementary scheme varying by chosen class; the 2026 PASS is set at 48,060 euros. A pharmacist may buy back retirement quarters for study years (up to twelve quarters), low-income early-career years and years worked abroad; the accountant calculates the actuarial return on the buy-back to decide whether it is financially worthwhile.

Alongside the CAVP, a retirement savings plan (PER) builds a supplementary capitalised pension with immediate tax deductibility. For a pharmacist in a SELARL at IS, a company PER funded by the company is deductible from the taxable result, and voluntary payments are deductible from the pharmacist's taxable income within the Madelin ceiling or the available retirement-savings allowance. A pharmacist with 90,000 euros of taxable income who pays 15,000 euros into a PER saves 15,000 euros at the 41 percent marginal rate, that is 6,150 euros of tax, for a net invested amount of 8,850 euros, an immediate return of plus 69 percent. Madelin contracts also let self-employed pharmacists deduct provident cover (deduction ceiling of 7 percent of profit plus 3.75 percent of the PASS), Madelin health cover, and supplementary pension cover (ceiling of 10 percent of profit plus 25 percent of the PASS, or 10 percent of the PASS if more favourable). The accountant sizes your Madelin envelope each year to maximise deductibility without exceeding the ceilings.

The stock of medicines and parapharmacy is generally the largest item on a pharmacy's balance sheet, representing between 20 and 40 days of turnover depending on the supply policy. Two valuation methods are used: first-in first-out (FIFO), valued at the most recent purchase price and recommended for medicines with expiry dates, and weighted average cost, better suited to slower-moving stock. The accountant organises your annual inventory procedure (or quarterly where needed): extracting the valued stock from the LGO, a counter-checked physical count with your team, treatment of discrepancies (unexplained shrinkage, expired goods, breakage), and recognition of provisions for impairment on expired or slow-moving products.

Working capital requirement is structurally high because you pay your suppliers (laboratories and wholesale distributors) before being reimbursed by the Assurance Maladie, on average 15 to 20 days later. Levers to optimise it include negotiating wholesaler payment terms, speeding up the SESAM-Vitale electronic transmission cycle for faster reimbursement, reducing dormant stock (products with no sale for more than 90 days), returning unsold goods to wholesalers, and taking supplier settlement discounts. The accountant tracks your forecast cash position month by month, building in spending peaks (stock renewal before the festive season, fit-out investment) and seasonal troughs.

A pharmacy is governed by the national collective agreement for retail pharmacy (IDCC 1996), which sets specific rules the accountant must master to secure your payslips. The classification grid runs from a junior preparer in Group I (coefficient 100) at a minimum gross monthly salary of around 1,900 euros, through a confirmed preparer in Group II (coefficients 120 to 150) at around 2,100 to 2,400 euros, an employed pharmacist in Group III (coefficient 200) at around 2,900 euros, a senior employed pharmacist in Group IV (coefficient 250 and above) at around 3,400 euros, to a responsible or principal pharmacist in Group V (coefficient 300 and above) at around 4,000 euros and more. Compulsory agreement-based premiums include a seniority premium of 1 percent per year of service from one year, a qualification premium for diploma-holding preparers (BTS), and on-call allowances for night, Sunday and public-holiday duty.

Specialist payroll management is essential in a sector where URSSAF inspections are frequent. The accountant calculates payslips in line with the agreement grids, manages the monthly social declaration (DSN) with automatic transmission to the relevant bodies, handles sick leave and workplace accidents (subrogation, daily allowances), manages paid leave, calculates employer contributions (around 42 to 45 percent of gross salary) and employee contributions, and runs the compulsory company health cover with the minimum 50 percent employer contribution.

Transferring a pharmacy can take several forms with radically different tax consequences. A sale of the goodwill means the pharmacy is sold as a business; the seller realises a gain subject to professional capital gains tax, while the buyer bears transfer duties. A sale of SEL shares, where the pharmacy is run through a SELARL, carries reduced transfer duties of 3 percent, and the seller's gain is taxed at the flat tax of 31.4 percent or the income tax scale, with a possible holding-period allowance under certain conditions. The contribution-and-sale mechanism under article 150-0 B ter of the tax code allows shares to be contributed to a holding controlled by the seller, with tax deferral if 60 percent of the sale proceeds are reinvested within two years, letting capital be redeployed before the gain is taxed. Finally, gifting before sale through a Dutreil pact applies under conditions to pharmacies run through a SEL for at least two years, granting a 75 percent exemption on the transferred value for gift or inheritance duty.

A pharmacy is valued by combining several methods: a multiple of turnover including VAT (70 to 100 percent), a multiple of restated EBITDA (5 to 7 times), corrected net assets (revalued book value), and the comparables method (price per square metre by area). Specific valuation points to check include the quality and stability of turnover over three years, dependence on local prescribers, the remaining term of the commercial lease and renewal conditions, the quality of the fixed assets (fit-out, LGO, robotic equipment), and the generic substitution rate and ROSP level. A dispensing robot or automated system can raise value by 5 to 8 percent depending on its condition and age, while a precarious lease or ageing prescribers may justify a discount of 10 to 15 percent.

When supporting a transfer, the accountant works in stages. Twelve to twenty-four months before, the accounting result is restated to reveal the true EBITDA, adding back excess remuneration, personal expenses recorded in the accounts and exceptional charges. During buyer due diligence, the financial statements are checked over three years, along with the VAT split, the stock and any potential employment disputes. The transfer is then structured, choosing between a sale of the business or of shares, optimising the gain and structuring the buyer's SPFPL. Bank financing is arranged with a seven-to-ten-year business plan presenting the normalised EBITDA, the repayment capacity and the initial working capital requirement. After the transfer, the seller is supported on declaring the gain, the available tax options and reinvestment.

A specialist accountant also secures your accounts against the reassessment risks pharmacies face: incorrect VAT splits (applying 20 percent to products that should be at 2.1 or 5.5 percent, which can lead to a VAT recovery over the last three years plus a 40 percent penalty for deliberate breach if systematic), reclassification of supplier rebates, poorly allocated mixed charges, under-declared ROSP, and URSSAF inspection of social contributions. The defence is a documented review file, built from monthly review of collected and deductible VAT, quarterly reconciliation of software, accounting and declared turnover, consistency checks on supplier rebates, and a year-end review of deductible charges.

The Rémunération sur Objectifs de Santé Publique (ROSP) is an annual payment from the Assurance Maladie, calculated on quality-of-dispensing indicators. For a well-positioned urban pharmacy it represents 8,000 to 25,000 euros a year depending on the size and dynamism of the team, so it is a meaningful, recurring source of income rather than a marginal extra. The main indicators for 2026 are the generic substitution rate (ROSG), with a target of at least 93 percent and a strong weighting; prescribing within the generic register, with a target of at least 75 percent and a medium weighting; the number of pharmaceutical interviews (for vitamin K antagonists, asthma and direct oral anticoagulants), with a strong weighting; support for hospital discharges, with a medium weighting; and shared medication reviews, with a growing weighting.

The accounting treatment of the ROSP is where pharmacies most often slip. Because the payment arrives with a lag, usually in the first half of the following year, the income belongs to the year in which the targets were met, not the year it lands in the bank. The accountant therefore provisions the estimated ROSP at each year-end as accrued income, so that the result reflects the performance actually delivered over the period. Skipping this step understates one year and overstates the next, distorting both the profit and loss account and any valuation built on it.

Steering the ROSP is as much an operational task as an accounting one. The accountant reviews the monthly ROSP dashboard available on Ameli Pro to anticipate where the pharmacy stands against each target, helps configure alerts in the dispensing software to flag substitutable prescriptions that were not substituted, and folds the expected ROSP into the tax and social result for the year. A two-point gap on the substitution rate, caught in June rather than discovered the following spring, is often enough time to recover the bonus. Treating the ROSP as a live indicator, not a year-end surprise, is one of the clearest examples of an accountant acting as a co-pilot rather than a record-keeper.

In 2026 a specialist pharmacy accountant must be able to connect your dispensing software (LGO) to their accounting software. This connection automates the import of daily sales split by VAT rate, the reconciliation of Assurance Maladie reimbursements through the SESAM-Vitale feed, real-time tracking of stock and supplier purchases, and automated bank reconciliation of wholesaler and Assurance Maladie flows. The benefit is twofold: the multi-rate VAT split stops being a manual, error-prone task, and the owner gains figures that are current rather than three months old.

The LGO landscape in 2026 is concentrated around a handful of systems, and the depth of accounting integration varies. Winpharma (PHARMAGEST) holds around 40 percent of the market and offers an open API with Pennylane and Sage connectors. LGPI (ALLIADIS) holds around 25 percent and works through CSV export plus a dedicated connector. Opus (CEGEDIM) holds around 15 percent with an available API connector. Pluspharmacie (PHR) holds around 10 percent with a standard export. The remaining 10 percent, including systems such as Pharmactiv, offer variable integration. Knowing which connection your LGO supports matters in practice, because it determines whether the monthly close can be largely automated or whether it relies on manual re-keying that reintroduces VAT-split errors.

From this data the accountant produces a monthly management report. On the financial side it covers turnover including VAT and its year-on-year change, gross margin by product family, forecast versus actual operating surplus, net cash and a three-month cash projection, and working capital with stock rotation. On the quality and compliance side it tracks the generic substitution rate against the ROSP target, the number of pharmaceutical interviews carried out, unexplained shrinkage as a percentage of stock, and the value of expired goods. On the social side it follows the payroll bill against budget, overtime and premiums under the pharmacy collective agreement, and absenteeism and replacement cost. A dashboard of this kind turns the annual accounts into a tool the owner can act on month by month, well before the year is closed.

The compulsory electronic invoicing reform has been rolling out progressively since 2024, and pharmacies are not exempt from it. Invoices issued to health professionals and to institutions must be dematerialised, through Chorus Pro for public-sector establishments or through partner platforms for private players. Inter-pharmacy transactions, such as locum arrangements and loans of medicines, are within scope. Transactions with private individuals at the counter remain outside the perimeter, but the dispensing software is evolving to make the underlying tracking easier.

The practical question for an owner is less about whether the reform applies and more about which partner dematerialisation platform (PDP) to choose and how to bring the information system into compliance. The accountant helps make that choice and align it with the LGO already in place, so that the e-invoicing flow connects cleanly to the existing dispensing and accounting setup rather than becoming a parallel channel that has to be reconciled by hand. Because the rollout is phased, the value of preparing early is avoiding a rushed switch later, when the same work must be done under a deadline rather than at a chosen pace.

Pharmacies are among the sectors the tax authorities monitor most closely, precisely because their multi-rate VAT is complex. The most common error is an incorrect VAT split, such as applying 20 percent to products that should be taxed at 2.1 or 5.5 percent, or the reverse. Where the error is systematic, the authorities can demand a VAT recovery over the last three financial years plus a 40 percent penalty for deliberate breach, which turns a configuration oversight into a significant liability. A second recurring issue is the reclassification of supplier rebates: year-end rebates from laboratories must be correctly recorded as a reduction of purchase cost, and a poor treatment can artificially inflate the deductible charges. A third is poorly allocated mixed charges, where personal expenses of the owner (car, telephone, meals) are recorded as pharmacy operating costs and can be added back on inspection.

Two further risks are easy to underestimate. The ROSP paid by the Assurance Maladie is taxable income, so omitting it or recording it late can constitute an irregularity, which is another reason the year-end provision matters. And URSSAF inspections, which are frequent in this sector, check that employees are correctly affiliated, that employer contributions are properly calculated, and that the general reduction in contributions is applied correctly.

The way an accountant protects against all of this is structural rather than reactive. It rests on a monthly review of the collected and deductible VAT accounts, a quarterly reconciliation of the dispensing-software turnover against the accounting turnover and the turnover declared for VAT, a consistency check on supplier rebates compared with the framework contracts, a year-end review of deductible charges to isolate mixed costs, and a documented review file. That file is the first line of defence in the event of an inspection, because it shows that the figures were checked as the year ran rather than assembled after the fact.

Two questions come up repeatedly, and both are decisions an owner should take with figures in front of them rather than on instinct. The first is when to move to a SELARL. The switch becomes worthwhile when the BNC profit exceeds 80,000 to 100,000 euros; below that level, the cost of setting up and running the company may not justify the tax gain. The right approach is a comparative three-year simulation, so the decision rests on projected reality rather than on a rule of thumb. The second is whether to hold the commercial premises through a separate property company. If you own the premises where you run the pharmacy, separating the property holding (through an SCI or directly) from the operation (the SELARL) is generally advisable: it makes transfer easier, lets the pharmacy pay a deductible rent, and protects the property assets if the business runs into difficulty.

Bringing in a partner is a third frequent situation. When an employed pharmacist wants to become an associate, several routes exist: a direct sale of SELARL shares, entry into the capital of an SPFPL, or the creation of a new SEL under joint ownership. Each has different tax and legal consequences, and the accountant coordinates the operation with a lawyer specialising in libéral company law so that the chosen route fits both the seller's and the junior partner's objectives. The same applies to multi-pharmacy ownership: through an SPFPL a pharmacist can hold up to five pharmacies in France, and since the HPST law groupings can go further within certain conditions, but the structure must be built deliberately rather than improvised.

On retirement, the pharmacist contributes compulsorily to the CAVP for both the basic and supplementary pension, with a legal retirement age of 64 following the 2023 reform; the CAVP pension depends on the number of points acquired and the value of the point at departure, which is why supplementing it with an individual or collective PER is strongly recommended. Across all of these decisions, the common thread is that the accountant is there to model the consequences before the choice is made, not only to record it once it has been taken. This guide informs; a decision specific to your situation needs a review of your figures, your documents and the law in force.

Contact Hayot Expertise for a free diagnosis of your pharmacy's accounting and tax situation.